A strategy to offset the extra cost of sirolimus-eluting stent in patients undergoing intervention for acute myocardial infarction

Compared to abciximab + BMS, tirofiban infusion + SES implantation in STEMI patients was an economically dominant strategy, with an improved composite outcome and lower overall costs.